Billions are spent on glucosamine supplements every year. Do they work? Are they safe?
Benefits and Side Effects of Glucosamine for Osteoarthritis
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Are there benefits to the osteoarthritis supplements, glucosamine and chondroitin? Watch this video and the next to see what the science says.
Global sales of glucosamine supplements are estimated at $2 billion. Glucosamine is a precursor to two of the major components of cartilage, though at the marginal blood levels achieved by supplementation, one would not expect it to contribute much to cartilage formation directly. There are marked inconsistencies in the clinical research literature as to whether it works at all. The most potent predictor of trial results? Industry funding. Studies sponsored by the product makers themselves showed their patented products were beneficial. But independently-funded studies showed glucosamine had no effect. This has raised serious concerns about “publication bias,” the suspicion that the glucosamine industry quietly shelved rather than published any studies that didn’t go their way to give an overly rosy picture in the medical literature. This is what led in part to the current American College of Rheumatology guidelines strongly recommending against the use of glucosamine.
The proscription against glucosamine is echoed by some expert consensus guidelines––for example, the American Academy of Orthopedic Surgeons and Osteoarthritis Research Society International, but not others, such as the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, which allows an exception for pharmaceutical-grade glucosamine. Only this patented so-called “crystalline” glucosamine, sold as a prescription-only drug in Europe, has been decisively shown to improve osteoarthritic joint pain or function, whereas the over-the-counter glucosamine supplements sold in the U.S. offered mixed results with no overall effect, presumably because quality control analyses by Consumer Reports and others found glucosamine supplements sometimes contained no glucosamine at all. An investigation of over a dozen glucosamine supplements found that only one contained the claimed dose on the label.
So, maybe the inconsistency in findings is less a matter of funding bias, and more a reflection of the efficacy of using genuine glucosamine. I’d feel more confident in the industry results if they were more transparent with their participant-level results. A request for data sharing was reportedly denied by the owner of the crystalline glucosamine trials, which “raises concerns about the robustness of their study findings.”
Regardless, the effect size of the pain relief found even in the best studies of crystalline glucosamine can be considered relatively small. Effect size can be quantified as a “standardized mean difference.” An effect size of 0.2 is considered small, 0.5 moderate, and 0.8 large. The effect size of the best studies of crystalline glucosamine, 0.27, representing a small effect. So, prescription glucosamine works better than Tylenol, but on par with placebo injections, and less than the NSAID drugs like ibuprofen. Now glucosamine is safer than NSAIDs, but the most tantalizing possibility is that it could offer more than just symptomatic relief.
Two industry-funded randomized controlled trials found that those with knee osteoarthritis randomized to take the prescription glucosamine for three years experienced less progression of their disease compared to placebo, as quantified by x-ray measurements. Those on the glucosamine had a 62 percent reduction in osteoarthritis progression, as measured by joint space narrowing, compared to those randomized instead to placebo. However, two subsequent non-industry studies found no benefit on osteoarthritis disease progression, resulting in no benefit overall when all four were combined. But, how’s this for a purported potential side-effect: a longer life?
Glucosamine supplementation extends the lifespan of both microscopic worms and aging mice. What about people? In 2012, the Vitamins and Lifestyle cohort was the first to report on the relationship between glucosamine use and mortality. About 75,000 Washington State residents aged 50 to 76 were followed for about seven years, and those taking glucosamine were 18 percent less likely to die in that period. In 2020, two other cohort studies were published on the matter, including the enormous UK Biobank study that followed nearly a half million people for nine years. Glucosamine users were 15 percent less likely to die, and in a 2020 national U.S. study, users had 27 percent lower risk of death. Since glucosamine use has been associated with lower CRP blood levels, researchers suggested that this may be an anti-inflammatory effect. But when actually put to the test, glucosamine doesn’t appear to affect CRP at all. A more likely explanation may be the so-called “healthy user effect.”
Those who choose to take supplements tend to be healthier than those who don’t. Studies show dietary supplement users are more likely to be female, more educated, and make healthier diet and lifestyle choices, such as exercising more and smoking less, and being less sick. So, presumably, that’s why observational studies found that those who take vitamins may have lower mortality rates, but when put to the test in interventional studies, there was no benefit, or worse. One of the most dramatic examples of the healthy user effect is the finding that elders who take flu vaccines appear to cut their risk of all-cause winter mortality by 50 percent, when seasonal flu itself rarely causes more than 10 percent of excess winter deaths. That’s why randomized controlled trials are so critical to establishing cause and effect, and we have no such data as of yet for glucosamine. The cohort studies did try to adjust for factors such as age, obesity, exercise, education, and smoking status, but it’s not possible to control for unmeasured lifestyle confounders.
Please consider volunteering to help out on the site.
- Knapik JJ, Pope R, Hoedebecke SS, Schram B, Orr R, Lieberman HR. Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis. J Spec Oper Med. 2018;18(4):139-147.
- Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65(2):222-226.
- Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum. 2007;56(7):2267-2277.
- Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee [published correction appears in Arthritis Rheumatol. 2021 May;73(5):799]. Arthritis Rheumatol. 2020;72(2):220-233.
- Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013;21(9):571-576.
- Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59-66.
- Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2005(2):CD002946.
- Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol. 2002;29(11):2407-2409.
- Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-1855.
- Runhaar J, Rozendaal RM, van Middelkoop M, et al. Response to: “Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms” by Reginster et al. Ann Rheum Dis. 2018;77(7):e40.
- Doshi R, Ostrovsky D. Glucosamine may be effective in treating pain due to knee osteoarthritis. Explore (NY). 2019;15(4):317-319.
- Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54.
- Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113-2123.
- Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-256.
- Veronese N, Demurtas J, Smith L, et al. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975927.
- Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851-858.
- Rozendaal RM, Koes BW, van Osch GJVM, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008;148(4):268-277.
- Weimer S, Priebs J, Kuhlow D, et al. D-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun. 2014;5:3563.
- Bell GA, Kantor ED, Lampe JW, Shen DD, White E. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27(8):593-603.
- Li ZH, Gao X, Chung VC, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Ann Rheum Dis. 2020;79(6):829-836.
- King DE, Xiang J. Glucosamine/chondroitin and mortality in a US NHANES cohort. J Am Board Fam Med. 2020;33(6):842-847.
- Kantor ED, Lampe JW, Vaughan TL, Peters U, Rehm CD, White E. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012;176(11):1002-1013.
- Ma H, Li X, Sun D, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019;365:l1628.
- Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 2007;27(3):213-218.
- Kofoed CLF, Christensen J, Dragsted LO, Tjønneland A, Roswall N. Determinants of dietary supplement use--healthy individuals use dietary supplements. Br J Nutr. 2015;113(12):1993-2000.
- Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546-550.
- Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165(3):265-272.
Motion graphics by Avo Media
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Are there benefits to the osteoarthritis supplements, glucosamine and chondroitin? Watch this video and the next to see what the science says.
Global sales of glucosamine supplements are estimated at $2 billion. Glucosamine is a precursor to two of the major components of cartilage, though at the marginal blood levels achieved by supplementation, one would not expect it to contribute much to cartilage formation directly. There are marked inconsistencies in the clinical research literature as to whether it works at all. The most potent predictor of trial results? Industry funding. Studies sponsored by the product makers themselves showed their patented products were beneficial. But independently-funded studies showed glucosamine had no effect. This has raised serious concerns about “publication bias,” the suspicion that the glucosamine industry quietly shelved rather than published any studies that didn’t go their way to give an overly rosy picture in the medical literature. This is what led in part to the current American College of Rheumatology guidelines strongly recommending against the use of glucosamine.
The proscription against glucosamine is echoed by some expert consensus guidelines––for example, the American Academy of Orthopedic Surgeons and Osteoarthritis Research Society International, but not others, such as the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, which allows an exception for pharmaceutical-grade glucosamine. Only this patented so-called “crystalline” glucosamine, sold as a prescription-only drug in Europe, has been decisively shown to improve osteoarthritic joint pain or function, whereas the over-the-counter glucosamine supplements sold in the U.S. offered mixed results with no overall effect, presumably because quality control analyses by Consumer Reports and others found glucosamine supplements sometimes contained no glucosamine at all. An investigation of over a dozen glucosamine supplements found that only one contained the claimed dose on the label.
So, maybe the inconsistency in findings is less a matter of funding bias, and more a reflection of the efficacy of using genuine glucosamine. I’d feel more confident in the industry results if they were more transparent with their participant-level results. A request for data sharing was reportedly denied by the owner of the crystalline glucosamine trials, which “raises concerns about the robustness of their study findings.”
Regardless, the effect size of the pain relief found even in the best studies of crystalline glucosamine can be considered relatively small. Effect size can be quantified as a “standardized mean difference.” An effect size of 0.2 is considered small, 0.5 moderate, and 0.8 large. The effect size of the best studies of crystalline glucosamine, 0.27, representing a small effect. So, prescription glucosamine works better than Tylenol, but on par with placebo injections, and less than the NSAID drugs like ibuprofen. Now glucosamine is safer than NSAIDs, but the most tantalizing possibility is that it could offer more than just symptomatic relief.
Two industry-funded randomized controlled trials found that those with knee osteoarthritis randomized to take the prescription glucosamine for three years experienced less progression of their disease compared to placebo, as quantified by x-ray measurements. Those on the glucosamine had a 62 percent reduction in osteoarthritis progression, as measured by joint space narrowing, compared to those randomized instead to placebo. However, two subsequent non-industry studies found no benefit on osteoarthritis disease progression, resulting in no benefit overall when all four were combined. But, how’s this for a purported potential side-effect: a longer life?
Glucosamine supplementation extends the lifespan of both microscopic worms and aging mice. What about people? In 2012, the Vitamins and Lifestyle cohort was the first to report on the relationship between glucosamine use and mortality. About 75,000 Washington State residents aged 50 to 76 were followed for about seven years, and those taking glucosamine were 18 percent less likely to die in that period. In 2020, two other cohort studies were published on the matter, including the enormous UK Biobank study that followed nearly a half million people for nine years. Glucosamine users were 15 percent less likely to die, and in a 2020 national U.S. study, users had 27 percent lower risk of death. Since glucosamine use has been associated with lower CRP blood levels, researchers suggested that this may be an anti-inflammatory effect. But when actually put to the test, glucosamine doesn’t appear to affect CRP at all. A more likely explanation may be the so-called “healthy user effect.”
Those who choose to take supplements tend to be healthier than those who don’t. Studies show dietary supplement users are more likely to be female, more educated, and make healthier diet and lifestyle choices, such as exercising more and smoking less, and being less sick. So, presumably, that’s why observational studies found that those who take vitamins may have lower mortality rates, but when put to the test in interventional studies, there was no benefit, or worse. One of the most dramatic examples of the healthy user effect is the finding that elders who take flu vaccines appear to cut their risk of all-cause winter mortality by 50 percent, when seasonal flu itself rarely causes more than 10 percent of excess winter deaths. That’s why randomized controlled trials are so critical to establishing cause and effect, and we have no such data as of yet for glucosamine. The cohort studies did try to adjust for factors such as age, obesity, exercise, education, and smoking status, but it’s not possible to control for unmeasured lifestyle confounders.
Please consider volunteering to help out on the site.
- Knapik JJ, Pope R, Hoedebecke SS, Schram B, Orr R, Lieberman HR. Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis. J Spec Oper Med. 2018;18(4):139-147.
- Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65(2):222-226.
- Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum. 2007;56(7):2267-2277.
- Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee [published correction appears in Arthritis Rheumatol. 2021 May;73(5):799]. Arthritis Rheumatol. 2020;72(2):220-233.
- Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013;21(9):571-576.
- Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59-66.
- Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2005(2):CD002946.
- Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol. 2002;29(11):2407-2409.
- Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-1855.
- Runhaar J, Rozendaal RM, van Middelkoop M, et al. Response to: “Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms” by Reginster et al. Ann Rheum Dis. 2018;77(7):e40.
- Doshi R, Ostrovsky D. Glucosamine may be effective in treating pain due to knee osteoarthritis. Explore (NY). 2019;15(4):317-319.
- Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54.
- Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113-2123.
- Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-256.
- Veronese N, Demurtas J, Smith L, et al. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975927.
- Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851-858.
- Rozendaal RM, Koes BW, van Osch GJVM, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008;148(4):268-277.
- Weimer S, Priebs J, Kuhlow D, et al. D-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun. 2014;5:3563.
- Bell GA, Kantor ED, Lampe JW, Shen DD, White E. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27(8):593-603.
- Li ZH, Gao X, Chung VC, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Ann Rheum Dis. 2020;79(6):829-836.
- King DE, Xiang J. Glucosamine/chondroitin and mortality in a US NHANES cohort. J Am Board Fam Med. 2020;33(6):842-847.
- Kantor ED, Lampe JW, Vaughan TL, Peters U, Rehm CD, White E. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012;176(11):1002-1013.
- Ma H, Li X, Sun D, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019;365:l1628.
- Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 2007;27(3):213-218.
- Kofoed CLF, Christensen J, Dragsted LO, Tjønneland A, Roswall N. Determinants of dietary supplement use--healthy individuals use dietary supplements. Br J Nutr. 2015;113(12):1993-2000.
- Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546-550.
- Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165(3):265-272.
Motion graphics by Avo Media
Republishing "Benefits and Side Effects of Glucosamine for Osteoarthritis"
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
Benefits and Side Effects of Glucosamine for Osteoarthritis
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
In the next video, I look at the science behind chondroitin for osteoarthritis.
I recently did a series on collagen supplements, which includes Collagen Supplements for Arthritis.
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.